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Abstract There is increasing recognition of the involve-
ment of the immune signaling molecule, tumor necrosis factor
(TNF), in the pathophysiology of stroke and chronic brain
dysfunction. TNF plays an important role both in modulating
synaptic function and in the pathogenesis of neuropathic pain.
Etanercept is a recombinant therapeutic that neutralizes
pathologic levels of TNF. Brain imaging has demonstrated
chronic intracerebral microglial activation and neuroinflam-
mation following stroke and other forms of acute brain injury.
Activated microglia release TNF, which mediates neurotox-
icity in the stroke penumbra. Recent observational studies
have reported rapid and sustained improvement in chronic
post-stroke neurological and cognitive dysfunction following
perispinal administration of etanercept. The biological
plausibility of these results is supported by independent evi-
dence demonstrating reduction in cognitive dysfunction,
neuropathic pain, and microglial activation following the use
of etanercept, as well as multiple studies reporting improve-
ment in stroke outcome and cognitive impairment following
therapeutic strategies designed to inhibit TNF. The causal
association between etanercept treatment and reduction in
post-stroke disability satisfy all of the Bradford Hill Criteria:
strength of the association; consistency; specificity; tempo-
rality; biological gradient; biological plausibility; coherence;
experimental evidence; and analogy. Recognition that chronic
microglial activation and pathologic TNF concentration are
targets that may be therapeutically addressed for years fol-
lowing stroke and other forms of acute brain injury provides
an exciting new direction for research and treatment.
Key Points
Accumulating evidence suggests that chronic post-
stroke intracerebral microglial activation and
neuroinflammation mediated by pathologic levels of
tumor necrosis factor constitute new therapeutic
targets that may persist for years after stroke.
Perispinal etanercept for chronic post-stroke
neurological and cognitive dysfunction is an
emerging treatment modality that may lead to rapid
and sustained clinical improvement in this patient
population.
1 Introduction
Post-stroke disability represents a major public health
problem throughout the world [1, 2]. Current drug
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treatments are grossly inadequate [1, 2]. The world stroke
research community recognizes the urgent need for
improved stroke treatments [3].
In February 2011, rapid improvement in cognition;
improvement in chronic neurological dysfunction; and
reduction in chronic, intractable post-stroke pain was noted
among a series of three patients treated off-label 13, 25,
and 36 months after stroke with a single dose of etanercept,
administered by perispinal injection [4]. Onset of clinical
response was evident within 10 min of the etanercept dose
in each patient [4]. Each patient received a second pe-
rispinal etanercept dose at 22–26 days after the first, which
was followed by additional improvement [4].
In December 2012, an observational study of 629
patients treated off-label with perispinal etanercept was
published [5]. The study included 617 consecutive patients
treated a mean of 42 months following stroke (‘the
617-patient stroke cohort’), and 12 patients following
traumatic brain injury (TBI) [5]. Statistically significant
improvements in neurological and cognitive function and
reduction in pain were noted in the stroke cohort [5]. Pe-
rispinal etanercept produced rapid improvement in a vari-
ety of chronic post-stroke neurological dysfunctions
(Table 1). The 2011 and 2012 etanercept post-stroke
studies are designated herein as ‘the etanercept stroke
studies’ [4, 5]. Perispinal etanercept for post-stroke neu-
rological dysfunction was invented and pioneered by the
senior author. Perispinal etanercept for this indication has
been explored clinically nearly exclusively by the senior
author, his colleagues, and a small group of independent
physicians who have trained in the perispinal etanercept
treatment method. The etanercept stroke studies are pre-
viously published studies of the senior author and
colleagues.
1.1 Perispinal Administration
Perispinal administration is a novel method of drug deliv-
ery. Its use to deliver etanercept for treatment of post-
stroke neurological dysfunction is necessitated by the fact
that etanercept has difficulty in traversing the blood–brain
barrier (BBB) in therapeutically effective concentration
when administered systemically, due in large part to its
high molecular weight (150,000 Da) [6]. This difficulty in
reaching the brain in therapeutic concentrations when
administered systemically is consistent with other studies
documenting limited (0.1–0.6 %) penetration of large
molecules into the brain when administered systemically
[7–9]. Perispinal administration of etanercept for treatment
of brain disorders involves needle injection overlying the
spine superficial (external) to the ligamentum flavum [4, 5,
10, 11]. Perispinal injection of etanercept is designed to
facilitate selective delivery of etanercept to the central
nervous system, as drugs administered posterior to the
spine are absorbed into the external vertebral venous
plexus (Fig. 1) [12, 13]. The external vertebral venous
plexus drains into, and is a component of, the cerebrospinal
venous system (Fig. 2) [10, 12, 14–18]. The anatomy and
physiology of the cerebrospinal venous system, a unique,
bi-directional vascular pathway, remains little known in the
general medical community, despite recognition in multi-
ple neurosurgical and anatomical publications [18–30].
Trendelenburg positioning may facilitate selective delivery
of etanercept into the brain after it reaches the cerebro-
spinal venous system [10, 31–35]. The cerebrospinal
venous system provides a direct vascular pathway to the
brain (Figs. 1, 2).
Lack of familiarity with the cerebrospinal venous
system and the novelty of etanercept’s neurological
effects may help explain the skepticism expressed by
some and provides a rationale for this article [36]. Do the
etanercept stroke studies survive a rigorous analysis with
respect to their suggestion of a causal association
between post-stroke etanercept treatment and clinical
improvement?
2 The Nine Criteria of Hill
To begin such an analysis of the etanercept stroke studies,
one may apply the well known criteria laid down by the
English epidemiologist and statistician, Sir Austin Brad-
ford Hill [37]. Hill pioneered the randomized clinical trial
and was the first to demonstrate the connection between
smoking and lung cancer. In his famous Presidential
Address to the Royal Society of Medicine, Hill presented
nine criteria for determining a causal association that
would become the well known ‘Bradford Hill Criteria’
[37]. Hill’s criteria are widely used in the evaluation of
causation, have already been applied in the field of neu-
rology, and have been recommended as a useful framework
for evaluating healthcare evidence [38–40]. Hill’s nine
criteria are as follows: strength of the association; consis-
tency; specificity; temporality; biological gradient; bio-
logical plausibility; coherence; experimental evidence; and
analogy.
2.1 Strength of the Association
The magnitude of the clinical improvements, as reflected
by the measures that were quantitated in the 617-patient
stroke cohort, including the time to walk 20 m, Montreal
Cognitive Assessment, visual analog scale for pain, etc. are
consistent with a strong clinical effect. The strength of the
association between perispinal etanercept treatment and
clinical effect is strong [5].
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2.2 Consistency
Statistically significant improvements in motor impair-
ment, sensory impairment, cognition, aphasia, pain, and
other areas of neurological dysfunction were noted, with
p values consistently less than 0.001 in the 617-patient
stroke cohort treated with perispinal etanercept [5]. The
consistency of the association in the perispinal etanercept
stroke studies between treatment and effect is high [4, 5].
Several recent studies using basic science stroke models
have documented favorable effects of tumor necrosis factor
(TNF) inhibition using TNF inhibitors other than etaner-
cept [41–44]. A single study found that etanercept
administered systemically was ineffective in an acute
stroke model, arguing for the necessity of using specialized
methods, such as perispinal delivery, to facilitate penetra-
tion of etanercept across the blood–cerebrospinal fluid
Table 1 Rapid improvement in chronic post-stroke neurological dysfunction following perispinal etanercept
Clinical effect Manifestations Reference
Statistically significant improvements
Motor function Increased strength, improved gait, stronger grip. Improvements in swallowing and
dysarthria
[4, 5]
Spasticity Decreased muscle tone, improved range of motion, decreased shoulder pain [4, 5]
Sensation Improved sensation [4, 5]
Cognition Improvements in cognitive testing scores and executive function [4, 5]
Psychological/behavioral
function
Improvements in mood, affect, and behavior. Reductions in depression and anxiety [4, 5]
Aphasia Improvements in speech and language function [4, 5]; see also
[11]
Pain Reductions in post-stroke pain, including post-stroke shoulder pain and allodynia [4, 5]
Case reports
Urinary incontinence Regained bladder sensation and control [5]
Pseudobulbar affect Reduction in excessive emotionalism [5]
Fig. 1 The vertebral veins. Reproduced from Gray and Holmes [72]
Fig. 2 The cerebrospinal venous system. Reproduced from Breschet
[70]
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barrier when treating brain disorders [7, 9, 32–35, 41, 45,
46].
2.3 Specificity
Neither of the etanercept stroke studies utilized a placebo
control group, which limits claims of specificity. However,
the clinical effects observed in the 617-patient stroke
cohort after perispinal etanercept treatment were signifi-
cant, and many of the results (such as rapid improvement in
vision, hearing, and motor function) cannot be explained
by any mechanism other than a novel treatment effect,
especially considering that patients were treated a mean of
3.5 years after their stroke [5]. The natural history of stroke
recovery is well known: the great majority of the neuro-
logical recovery occurs in the first 6 months [47–49]. The
spectrum of clinical improvement across domains, includ-
ing improvements in motor function, cognition, sensory
function, aphasia, etc., as documented in the etanercept
stroke studies (see Case 1 in the 2011 etanercept stroke
study, for example) can only be explained by the occur-
rence of a specific and novel therapeutic effect [4, 5]. The
specificity of the association in the etanercept stroke
studies between treatment and effect is high.
2.4 Temporality
The temporal relationship between the time of etanercept
administration and clinical effect is remarkably strong, since
clinical improvement characteristically was observed within
minutes of the first dose in both etanercept stroke studies [4, 5].
2.5 Biological Gradient
Hill’s biological gradient criteria are meant to examine
whether increased exposure to the agent in question is
associated with an increased biological effect. ‘‘Exposure
can be characterized in different ways such as … the
duration of exposure… average exposure… or cumulative
exposure’’ [50]. Case reports included within the etanercept
stroke studies document enhanced therapeutic responses
after additional doses of etanercept in certain patients [4,
5]. Subsequent clinical experience has confirmed additional
neurological improvement after additional etanercept doses
in multiple patients.
2.6 Biological Plausibility
Biological plausibility is included in the Hill Criteria, with
a caveat:
‘‘It will be helpful if the causation we suspect is
biologically plausible. But this is a feature I am
convinced we cannot demand. What is biologically
plausible depends upon the biological knowledge of
the day … In short, the association we observe may
be one new to science or medicine and we must not
dismiss it too light-heartedly as just too odd. As
Sherlock Holmes advised Dr. Watson, ‘when you
have eliminated the impossible, whatever remains,
however improbable, must be the truth.’’’
The evidence supporting biological plausibility is elab-
orated in detail in Sects. 2.1–2.9.5 and in Table 2. The
recent peer-reviewed report of immediate and profound
neurological and cognitive improvement following pe-
rispinal etanercept injection more than 3 years after acute
brain injury provides additional support for the plausibility
of rapid neurological improvement following perispinal
etanercept for chronic post-stroke neurological and cogni-
tive dysfunction [11].
2.7 Coherence
Reviewing the evidence discussed herein, the published
results of perispinal etanercept for post-stroke disability are
consistent with the following: (1) known involvement of
TNF in the pathophysiology of chronic brain dysfunction in
multiple diseases and disorders (review: [32]; 34, 51–62],
Table 2); (2) the role of TNF in the pathophysiology of
stroke, as discussed herein; (3) the existence of chronic,
post-stroke intracerebral glial activation and neuroinflam-
mation, as established by neuroimaging and pathological
examination, as discussed herein; and (4) the known ability
of etanercept to both rapidly neutralize pathologic TNF and
reduce glial activation (Table 2) [45, 63–67].
Additionally, the novel clinical results reported, such as
rapid improvement in vision and hearing, etc., may well be
attributed to the fact that a potent biologic therapeutic (e-
tanercept) is being administered by a novel route of
administration (perispinal). Perispinal administration is
designed to deliver etanercept into the cerebrospinal
venous system as a method to enhance transport of eta-
nercept across the blood–cerebrospinal fluid barrier [10, 16,
31, 35, 68, 69]. The unique anatomy and physiology of
these interconnected venous plexuses is supported by a
long series of experimental and pathological investigations
recognized by those in the field, particularly in the neuro-
surgical community [10, 12, 14–19, 27, 31, 35, 68–79].
2.8 Experimental Evidence
Experimental evidence, according to Hill, is where ‘‘the
strongest support for the causation hypothesis may be
revealed’’ [37]. The experimental evidence supporting the
use of perispinal etanercept for post-stroke neurological
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dysfunction is outlined in Table 2. The evidence, as
reviewed in the previous and subsequent sections herein,
can be separated into the following main categories:
2.8.1 Experimental Evidence in Multiple Models Suggests
Pathologic Tumor Necrosis Factor (TNF)
is Centrally Involved in the Pathophysiology
of Stroke
Experimental evidence implicating TNF in stroke patho-
physiology was published in 1994, and has continued
through the present [80–89]. A recent study investigated
the long-term consequences of subarachnoid hemorrhage
(SAH) on behavior, neuroinflammation, and damage to
gray and white matter in Wistar rats through day 21 post-
insult [90]. Severe SAH induced significant gray- and
white-matter damage and changes in multiple cytokines,
including increased expression of TNF at 48 h post-insult
[90]. Neuroinflammation, including microglial activation,
was ‘‘very long-lasting and still present at day 21’’ and
accompanied by changes in sensorimotor behavior [90].
2.8.2 Experimental Evidence in Multiple Models Provides
Data Demonstrating Improvement in Stroke
Outcome Through Inhibition of TNF
TNF was identified as a mediator of post-stroke focal
ischemic brain injury 2 decades ago [80–82, 89]. Specific
inhibition of TNF, using antibodies or other recombinant
TNF inhibitors, was found to reduce neurological damage
from stroke, improving stroke outcomes [80–82, 88, 89].
In 2013, inhibition of TNF using three different
molecular approaches yielded favorable results in three
separate animal models [42–44]. Researchers from Duke
summarized the scientific rationale and their results as
follows:
Intracerebral hemorrhage is a devastating stroke sub-
type characterized by a prominent neuroinflammatory
response. Antagonism of pro-inflammatory cytokines
by specific antibodies represents a compelling thera-
peutic strategy to improve neurological outcome in
patients after intracerebral hemorrhage… Post-injury
treatment with the TNF-alpha antibody CNTO5048
resulted in less neuroinflammation and improved
functional outcomes in a murine model of intracere-
bral hemorrhage …. TNF-alpha does not serve as a
simple ‘‘biomarker’’ of inflammation, but rather plays
a central role in mediating and extending neuronal
injury after insult … Monoclonal antibodies against
TNF-alpha make sense as a therapeutic strategy in
intracerebral hemorrhage due to the marked neuroin-
flammatory effects seen in this disease [43].
Increased peri-hematomal expression of TNF has been
functionally associated with neurovascular injury in multi-
ple species and experimental models of intracerebral hem-
orrhage (ICH) [91–96]. These findings are consistent with
clinical reports that found elevated cerebrospinal fluid and
plasma concentrations of TNF directly correlated with acute
hematoma enlargement, edema development, and poor
patient outcomes after ICH [97–102]. In contrast to the
early clinical success of biologic inhibitors, which directly
bind TNF as a decoy receptor, small molecule inhibitors of
TNF signaling pathways remain largely unexplored after
ICH. TNF induces biological activity via stimulation of the
TNF receptors (TNFR1 and TNFR2) [103, 104]. Post-ICH
administration of R-7050, a novel cell-permeable triazolo-
quinoxaline compound that prevents the association of
TNFR with intracellular adaptor molecules [105], reduced
vasogenic edema and improved neurological outcomes in a
mouse model of ICH [42]. These studies raise the possi-
bility that small molecule inhibitors of TNF-TNFR signal-
ing may possess therapeutic potential after ICH.
A further mechanism to not only mitigate TNF-mediated
actions and signaling after ICH but also to aid in defining
their roles is to inhibit TNF generation. The controversial
sedative, thalidomide, has immunomodulatory actions that
are mediated, in large part, by lowering the rate of TNF
synthesis [106, 107]. Recent analogs that more effectively
achieve this include 3,60-dithiothalidomide (3,60-DT) [108],
which readily enters the brain [109] and suppresses TNF
synthesis post-transcriptionally at the level of translational
regulation via the 30-untranslated region of its messenger
RNA (mRNA) [108, 110] as well as through down-regu-
lation of the eukaryotic elongation initiation factor (eIF)-
4E [111] to allow its rapid degradation.
In a mouse model of focal ischemic stroke in which brain
TNF levels were found to be rapidly elevated within both
ipsi- and contralateral brain, 3,60-DT fully ameliorated this
rise and reduced infarct volume, neuronal death, and neu-
rological deficits [112]. This neuroprotection was accom-
panied by reduced inflammation, with 3,60-DT lowering the
expression of interleukin (IL)-1Beta and inducible nitric
oxide synthase, reducing activated microglia/macrophages,
astrocyte, and neutrophil numbers, and decreasing the
expression of intercellular adhesion molecule (ICAM)-1
within ischemic brain tissue [112]. TNF plays a role in the
induction of ICAM-1 expression and also promotes BBB
leakage by inducing the expression of matrix metallopro-
teinase (MMP)-9 [113, 114], which degrades BBB tight
junction proteins [115, 116]. Mitigating the rise in TNF by
3,60-DT treatment suppressed the known TNF-induced
activation of MMP-9 [117] and, thereby, decreased stroke-
induced BBB disruption by preserving junction proteins
[112]. In support of a major role of TNF in processes
mediating stroke as well as TNF inhibition as the primary
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mechanism for the neuroprotective action of 3,60-DT, the
ability of 3,60-DT to decrease ischemic brain damage was
abolished in mice lacking TNF receptors [112].
The mechanisms underlying the detrimental effects of
TNF signaling after ICH remain poorly defined and could
provide additional therapeutic targets upon elucidation.
Emerging data suggest that TNF induces necroptosis, a
novel form of cell death with characteristic features of
apoptosis, necrosis, and type 2 autophagic death [118–
121]. In an experimental model, hemorrhagic injury
increased TNF expression and promoted necroptotic cell
death in cultured glial cells [122]. This effect was reversed
by inhibition of receptor-interacting serine/threonine-pro-
tein kinase (RIPK)-1, a multi-functional protein kinase that
interacts with TNFR to activate the pro-inflammatory
transcription factor, nuclear factor (NF)-jB [123–125]. In
line with this finding, it was observed that necrostatin-1, a
pharmacological inhibitor of RIPK [124, 125], similarly
limited neurovascular injury and improved outcomes in a
pre-clinical model of ICH [126]. This finding is also con-
sistent with reports showing necrostatin-1 is neuroprotec-
tive in experimental models of ischemic stroke and TBI
[125, 127, 128]. Taken together, these experimental results
support the assertion that TNF induces detrimental effects
after neurological injury and suggests that directed target-
ing of TNF and downstream signaling pathways may
improve patient outcomes.
Additional research involving multiple animal models of
stroke and TBI provides documentation of a favorable
therapeutic response to TNF inhibition [42–45, 60, 61, 81,
82, 86, 129]. As an example, brain TNF levels were found
to have elevated rapidly (within 1 h) following concussive
(weight drop-induced) mild TBI in mice, and were maxi-
mal at 12 h [109]. Inhibition of this TBI-induced rise by
administration of a single dose of the TNF synthesis
inhibitor 3,60-DT fully ameliorated cognitive impairments
evaluated both 7 and 30 days later; supporting both a role
for TNF in TBI-induced neuroinflammation/cognitive
impairment and its targeting for treatment [109]. Most
recently, inhibition of phosphoinositide 3-kinase delta, a
molecule that controls intracellular TNF trafficking in
macrophages, was shown to reduce TNF secretion and
neuroinflammation and confer protection in a mouse
cerebral stroke model [130].
2.8.3 Positron Emission Tomographic Brain Imaging
and Pathologic Evidence Demonstrate that Chronic
Glial Activation and Neuroinflammation May Last
for Years after Stroke and Other Forms of Acute
Brain Injury
In 1988, researchers used autoradiography to investigate
the effects of cerebral infarction induced by unilateral
middle cerebral artery occlusion in rats. The radiolabeled
ligand PK11195 that binds primarily to activated microglia
was used. Seven days after stroke, [3H]PK11195 bound
significantly in the cortical and striatal regions surrounding
the focus of cerebral infarction with smaller increases in
the ventrolateral and posterior thalamic complexes and in
the substantia nigra, all ipsilateral to the occlusion [131].
In 1991, increased [3H]PK11195 binding in the thala-
mus during the second week after experimentally induced
stroke in rats was found using ex vivo autoradiography, at a
time when [3H]PK11195 binding around the primary lesion
was beginning to subside [132].
In 2000, a multi-national European academic collabo-
ration of neurologists, neuroscientists, and nuclear medi-
cine specialists demonstrated that brain inflammation may
persist for months or years after stroke in humans [133].
The physicians and scientists investigated the potential of
positron emission tomography (PET) using [11C]PK11195
to assess the microglial reaction in secondary thalamic
lesions in patients with infarcts in the territory of the
middle cerebral artery. All patients studied were found to
have increased [11C]PK11195 binding in the ipsilateral
thalamus, indicating microglial activation in projection
areas remote from the primary lesion [133]. The only
patient studied more than 7 months after stroke was a
50-year-old patient with a primary stroke involving the left
temporo-parietal region, and he demonstrated bilateral
thalamic microglial activation 24 months after stroke
[133].
In 2004, an international collaboration of neuroscientists
found pathological evidence of a long-term intracerebral
inflammatory response after TBI in a series of patients who
had sustained blunt head injury. They described microglial
hyperplasia and hypertrophy with major histocompatibility
complex (MHC) class II upregulation, and inflammatory
changes up to 16 years after the injury [134].
In 2005, Gerhard et al. [135], in another international
collaboration of academic scientists and physicians, studied
a series of patients between 3 and 150 days after onset of
ischemic stroke in order to measure the time course of
microglial activation. Utilizing (R)-[11C]-PK11195 PET,
they found that brain inflammation was long-lasting after
stroke, with (R)-[11C]-PK11195 binding involving both the
area of the primary lesion and areas distant from the pri-
mary lesion site [135]. They described the spread of the
glial response beyond the ischemic core as closely resem-
bling the progression of microglial activation in animal
experiments, with ‘‘early recruitment of microglia in the
ischemic border zone and later involvement of the neo-
cortex and thalamus’’ [135].
In 2006, Price et al. [136], in a multi-center academic
collaboration, used (R)-[11C]-PK11195 imaging to study a
series of patients after stroke. Using this imaging
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methodology, they documented persistent neuroinflamma-
tion in the stroke penumbra and elsewhere in the brain in
patients following stroke, and recognized that this neuro-
inflammatory response might represent a therapeutic
opportunity that extends beyond time windows tradition-
ally reserved for neuroprotection [136].
In 2011, Folkersma et al. [137], studied microglial
activation in patients with moderate and severe TBI
using (R)-[11C]-PK11195 brain PET, 6 months after
trauma. In both whole-brain and regional analysis,
increased (R)-[11C]-PK11195 binding potential was
found compared with age- and sex-matched healthy
controls. From these series, increased (R)-[11C]-
PK11195 binding potential was found not only in the
ipsilateral but also in the contralateral hemisphere,
indicating prolonged and widespread microglia activa-
tion after TBI.
Subsequent studies, using either PET imaging or path-
ologic examination, have confirmed the existence of
chronic intracerebral glial activation that has been docu-
mented to last for 17 years after even a single acute brain
injury [138, 139].
Microglial imaging using (R)-[11C]-PK11195 brain
PET can be of meaningful clinical and diagnostic value
in terms of visualization and quantification of active
neuroinflammatory and neurodegenerative disease pro-
cesses and in elucidation of the long-term effects of
neuroinflammatory sequelae and its implications for
neurological outcome [137]. Taken together, along with
additional research showing that pathologic TNF medi-
ates neurotoxicity in the ischemic penumbra, these data
suggest that chronic microglial activation and neuroin-
flammation may be a common pathological response to
stroke and other forms of acute brain injury [86,
133–140].
There is a need to understand the long-term relation-
ship between late microgliosis and TNF. Although the
PET data discussed in this section do not describe TNF
actions or changes, PET imaging before and after thera-
peutic intervention with TNF inhibitors that can quantify
and describe patterns of microglial activation promises to
be a fertile area for future investigation. As suggested by
Price et al. [136], the accumulating evidence indicates
that chronic glial activation after acute brain injury rep-
resents a therapeutic target that persists far longer than
the time windows traditionally reserved for neuroprotec-
tion. This evidence provides a scientific basis for con-
sidering pharmacologic therapeutic intervention that
targets chronic glial activation months or years after
stroke, and supports the plausibility of achieving a ther-
apeutic response in patients with chronic post-stroke
neurological dysfunction by targeting pathologic TNF
concentration [86, 133–139].
2.8.4 Experimental Evidence Implicates TNF
in the Neurotoxicity Produced by Glial Activation
in the Stroke Penumbra
In an in vitro model of microglial activation and propa-
gated neuron killing in the stroke penumbra, TNF inhibi-
tion using a soluble TNF receptor reduced neurotoxicity
[86]. In addition, experimental data suggest that TNF
functions as a gliotransmitter that is involved in the
mechanisms whereby glia modulate synaptic transmission
and neuronal network function [141–155].
2.8.5 Etanercept is Both a Potent TNF Inhibitor
and an Inhibitor of Microglial Activation
The plausibility of beneficial effects of etanercept for
treatment of chronic post-stroke neurological dysfunction
is supported by the fact that, in addition to its known role as
a potent biologic inhibitor of TNF, etanercept has also been
shown to be capable of reducing glial activation in multiple
experimental models [45, 64–67]. The known physiologi-
cal effects of etanercept on TNF and glial activation make
it a well matched candidate to address the chronic glial
activation and pathologic TNF that may be a long-lasting
consequence of stroke [45, 64–67, 86, 133, 135, 136].
2.9 Analogy
Review of the medical literature provides evidence sup-
porting the plausibility of the results of the etanercept
stroke studies by analogy, as discussed below.
2.9.1 Etanercept and Other Biologic TNF Inhibitors
Reduce Neuropathic Pain
Statistically significant improvements in pain, including
improvements in hyperesthesia, allodynia, pain associated
with spasticity, post-stroke shoulder pain, and neuropathic
pain were reported in the 617-patient stroke cohort [5].
These results are supported by a long series of experiments
documenting the effects of etanercept and other biologic
TNF inhibitors in experimental models and in the clinic.
In 1998 and thereafter, Sommer and colleagues [156–
158], in a series of basic science experiments, demon-
strated the central involvement of TNF in the pathophysi-
ology of neuropathic pain and the favorable effects of anti-
TNF antibody treatment in these models. In 1999, a sepa-
rate group of investigators [159] showed that neuropathic
pain was mediated by brain-derived TNF. Subsequent
studies provided further supportive evidence [159–165]. In
2001, etanercept was shown to reduce hyperalgesia in
experimental painful neuropathy [166]. In 2003 and 2004,
the first human evidence of the effectiveness of etanercept
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for treating neurological spinal pain was published [167–
170]. Many of these early studies were performed by the
authors and their colleagues. Subsequently, four random-
ized controlled clinical trials have provided favorable data
supporting the efficacy of etanercept for neurological
spinal pain, and TNF inhibition is emerging as a treatment
strategy for intractable sciatica and other forms of inter-
vertebral disc-related pain [171–176]. The accumulated
evidence is substantial [65, 156–175, 177–179]. This evi-
dence, taken together, suggests by analogy the plausibility
of pain improvement following etanercept in patients with
chronic post-stroke pain.
2.9.2 TNF is Centrally Involved in the Pathophysiology
of Chronic Brain Dysfunction in Multiple Disease
States
Statistically significant reduction in cognitive impairment
is reported in the 617-patient stroke cohort following pe-
rispinal etanercept treatment [5]. The data included
improvement in a standardized instrument, the Montreal
Cognitive Assessment, with p-values less than 0.0001
immediately post-treatment and 1 and 3 weeks later [5].
The cognitive improvement documented in the etanercept
stroke studies is supported, by analogy, by substantial
scientific evidence that suggests that TNF is centrally
involved in the pathophysiology of chronic brain
dysfunction.
Beginning in the 1980s, and continuing into the present,
TNF has been implicated in the pathophysiology of mul-
tiple diseases and disorders associated with chronic brain
dysfunction, including cerebral malaria [32, 51, 56, 180–
185]; TBI [45, 52, 60, 61, 129, 186, 187]; Alzheimer’s
disease [32, 34, 53, 55, 59, 149, 188–203], frontotemporal
dementia [54]; primary progressive aphasia [62, 204];
sarcoidosis [205]; rheumatoid arthritis [206]; surgery-
induced cognitive decline [57]; and a wide variety of
additional diseases and disorders [32, 58, 67, 207]. For
example, an increasing body of evidence supports a major
role for central neuroinflammatory mechanisms in the
pathogenesis of hepatic encephalopathy, a neuropsychiatric
complication of both acute and chronic liver failure. Mi-
croglial activation in liver failure has been attributed to the
accumulation of lactate in the brain, and focal accumula-
tion of brain lactate is a common feature of stroke, TBI,
and status epilepticus, conditions that are known to result
in significant neuroinflammation [67, 208]. Neuroinflam-
mation characterized by microglial activation and
increased expression of pro-inflammatory cytokines in the
brain has been reported in both human and experimental
liver failure of diverse etiology, including viral hepatitis
[208] and biliary cirrhosis [209], as well as in acute liver
failure resulting from toxic [210] or ischemic [211] liver
injuries. Microglial activation and increased pro-inflam-
matory cytokine expression are significantly correlated
with the grade of encephalopathy in these disorders.
Moreover, slowing of hepatic encephalopathy progression
has been demonstrated following inhibition of microglial
activation by hypothermia [211] or minocycline [212] and
following the use of anti-TNF strategies such as etanercept
[213]. TNFR gene deletion delays the progression of
hepatic encephalopathy in mice with acute liver failure
resulting from toxic liver injury [210].
2.9.3 Infusion of Recombinant Human TNF Produced
Focal Neurological Dysfunction in Early Human
Studies, Supporting a Role of Excess TNF
in the Pathogenesis of Such Disorders
Additionally, it is notable that among the 69 patients who
participated in the early phase I studies of prolonged (24-h
or 5-day) intravenous infusions of recombinant human
TNF, three developed transient focal neurological symp-
toms. One patient developed diplopia, lethargy, and
expressive dysphasia after receiving recombinant TNF at
2.0 9 105 U/m2/d for 2 days, with return to baseline neu-
rologic status within 48 h without sequelae [214]. The
second study, involving a 24-h infusion of human recom-
binant TNF documented two cases of neurological toxicity,
as follows:
Two elderly patients had transient episodes of focal
neurological deficits. One patient had an isolated loss
of recent memory, while the other had transient
expressive aphasia. No abnormalities were noted
upon computerized tomography brain scan or cere-
brospinal fluid analysis. In each case, the symptoms
occurred near the completion of treatment and
resolved without sequelae within 6 h. These two
toxic events occurred at doses of 182 and 327 lg/m2
and did not represent dose-limiting toxicity [215].
These early cases of focal neurological toxicity fol-
lowing TNF infusion provide further scientific support for
the involvement of excess TNF in the pathophysiology of
post-stroke neurological dysfunction and the perispinal e-
tanercept results.
2.9.4 Specific Evidence Suggests that Etanercept
has the Potential to Reduce Cognitive Impairment
in Multiple Disorders Associated with Chronic Brain
Dysfunction
Etanercept has demonstrated favorable effects in neuroin-
flammatory disorders, both in the clinic and in multiple
experimental models [4, 5, 10, 35, 45, 58, 60, 61, 64–69,
146, 166–173, 177–179, 204, 207, 216–221].
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TNF levels in the cerebrospinal fluid 25 times higher
than in controls have been found in patients with Alzhei-
mer’s disease [222]. In patients with mild cognitive
impairment (MCI) followed prospectively, ‘‘only MCI
patients who progressed to Alzheimer’s disease at follow
up, showed significantly higher CSF levels of TNF-alpha
than controls … Indicating that CNS inflammation is a
early hallmark in the pathogenesis of AD’’ [223]. A later
study from these investigators supported this conclusion
regarding the role of TNF in Alzheimer’s disease patho-
genesis [224].
In 2006, the clinical results of a prospective, single-
center, open-label, pilot clinical trial of perispinal etaner-
cept for Alzheimer’s disease was reported by the senior
author and colleagues [216]. The authors included two
neurologists, a rheumatologist, and an internist, and the
study included 15 patients treated with perispinal etaner-
cept weekly over a period of 6 months [216]. The main
outcome measures included three standard instruments for
measuring cognition: the Mini-Mental State Examination
(MMSE), the Alzheimer’s Disease Assessment Scale-
Cognitive subscale (ADAS-Cog), and the Severe Impair-
ment Battery (SIB). There was significant improvement
with treatment, as measured by all of the primary efficacy
variables, through 6 months: MMSE increased by
2.13 ± 2.23 (p \ 0.003), ADAS-Cog improved
(decreased) by 5.48 ± 5.08 (p \ 0.006), and SIB increased
by 16.6 ± 14.52 (p \ 0.04).
In 2008, rapid cognitive improvement in a patient with
Alzheimer’s disease following treatment with perispinal
etanercept was reported by the senior author and a neu-
rologist [218]. Sue Griffin, co-editor of the Journal of
Neuroinflammation, reported her independent observations
after witnessing rapid clinical improvement in additional
patients with Alzheimer’s disease following treatment with
perispinal etanercept [217]. Subsequent publications by the
senior author and colleagues documented cognitive
improvement in patients with Alzheimer’s disease and
other forms of dementia following treatment with perispi-
nal etanercept [10, 68, 69, 146, 204, 219].
In a basic science study conducted by the senior
author and Stanford scientists and published in 2009,
perispinal administration of radiolabeled etanercept fol-
lowed by head-down positioning was discovered to
deliver radiolabeled etanercept into the choroid plexus
and cerebrospinal fluid within the cerebral ventricles
within minutes of injection, as visualized by PET scan
[31].
In 2010, Chio et al. [45] studied etanercept in an
experimental model of TBI. They found that etanercept
caused attenuation of TBI-induced cerebral ischemia,
reduction of motor and cognitive function deficits, and
reduction of microglial activation [45].
Chen et al. [206] studied the effects of anti-TNF treat-
ment on cognition in 15 patients with rheumatoid arthritis
over a period of 6 months with subcutaneous anti-TNF
treatment: eight received etanercept 25 mg twice weekly
and seven received adalimumab 40 mg twice monthly.
Cognitive function determined by MMSE scores was sig-
nificantly improved in the patient cohort [206].
Elfferich et al. [205] studied 343 sarcoidosis patients
over a period of 6 months, with all patients completing the
Cognitive Failure Questionnaire (CFQ) at baseline and at
6 months [206]. Patients were separated into three groups:
(1) no immunomodulating drugs; (2) prednisone with or
without methotrexate; and (3) anti-TNF drugs. Only
patients receiving anti-TNF drugs demonstrated a signifi-
cant improvement in CFQ score [205].
Chou et al. [225] presented the results of their review of
medical and pharmacy claims data from January 2000 to
November 2007 for a commercially insured cohort of 8.5
million adults throughout the USA. They derived a sub-
cohort of 42,193 patients with a pre-existing diagnosis of
rheumatoid arthritis. In this population of adults with
rheumatoid arthritis, they found a 55 % decreased inci-
dence in Alzheimer’s in those patients treated with TNF
inhibitors, but not with other disease-modifying agents
used for treatment of rheumatoid arthritis [225]. When they
further analyzed the risk according to the individual anti-
TNF agent used, they found that only etanercept was sig-
nificantly (p = 0.024) associated with reduced risk [226].
In 2011, Shi et al. [195, 196] reported cognitive
improvement in a woman with Alzheimer’s disease fol-
lowing intrathecal administration of infliximab, a chimeric
TNF monoclonal antibody, following the favorable results
of the use of infliximab in an experimental Alzheimer’s
model [195, 196].
In 2012, Gabbita et al. [227] found that early interven-
tion with a small molecule inhibitor of TNF prevented
cognitive deficits and improved the ratio of resting to
reactive microglia in the hippocampus in a murine triple
transgenic model of Alzheimer’s disease. Belarbi et al.
[228] found that a TNF protein synthesis inhibitor restored
neuronal function and reversed cognitive deficits induced
by chronic neuroinflammation. McNaull et al. [197, 229]
and Butchart and Holmes [197, 229] discussed the rationale
for TNF inhibition as a treatment approach for Alzheimer’s
disease in their review articles [197, 229].
Bassi and De Filippi [207] reported verbal, cognitive,
and behavioral improvement in a patient with long-stand-
ing neurological dysfunction, in whom etanercept was used
for treatment of psoriasis. The beneficial effect on cogni-
tion and social interaction was a surprising side effect of
etanercept used to treat the cutaneous psoriasis [207].
In 2013, Cheong et al. [197, 229] studied etanercept in
an experimental model of TBI. They found that
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neurological and motor deficits, cerebral contusion, and
increased brain TNF-alpha contents caused by TBI were
attenuated by etanercept [60].
In 2014, Detrait et al. [197, 229] reported favorable
effects of etanercept administered systemically in a basic
science Alzheimer’s model [230]. However, the only dose
that was effective across all measures of efficacy was the
highest dose, 30 mg/kg given every 2 days (for a total dose
of 90 mg/kg given during the first week). This 90-mg/kg
weekly dose is more than 100 times the normal human
etanercept dose. Etanercept doses of 3 mg/kg every 2 days,
about 15 times the usual human dose, were not effective.
The lack of efficacy of systemically administered etaner-
cept in this Alzheimer’s disease model at doses closer to
the usual human therapeutic dose is consistent with a
previous Alzheimer’s disease clinical trial in which eta-
nercept administered systemically at a dose of 25 mg twice
weekly was not found to be effective [231].
The totality of this evidence suggests, by analogy, the
plausibility of cognitive improvement following perispinal
administration of etanercept in patients with chronic post-
stroke cognitive impairment.
2.9.5 Independent Eye-Witness Observations
Finally, rapid neurological improvement following pe-
rispinal etanercept has been witnessed first-hand by inde-
pendent third parties, including several of the authors of
this commentary as well as others [11, 35, 216, 217, 232].
A new report has documented that a single dose of pe-
rispinal etanercept produced an immediate, profound, and
sustained improvement in expressive aphasia, speech
apraxia, cognitive dysfunction, and left hemiparesis in a
patient with chronic, intractable, debilitating neurological
dysfunction present for more than 3 years after acute brain
injury [11]. Replication of experimental results with vali-
dation by different observers is a time-honored cardinal
scientific principle supporting the reliability of a scientific
observation [39].
3 Conclusion
In summary, perispinal etanercept for post-stroke neuro-
logical and cognitive dysfunction satisfies all of Hill’s nine
criteria: strength of the association; consistency; specific-
ity; temporality; biological gradient; biological plausibility;
coherence; experimental evidence; and analogy.
The Oxford Centre for Evidence-Based Medicine
(OCEBM) is widely regarded as an authority in the
development of evidence-ranking schemes in medicine
[233]. OCEBM documents ‘‘a growing recognition that
observational studies—even case-series and anecdotes can
sometimes provide definitive evidence’’ and allows for
‘‘observational studies with dramatic effects to be ‘upgra-
ded’’’ with respect to level of evidence. The current evi-
dence hierarchy standard promulgated by the OCEBM
ranks observational studies that demonstrate dramatic
effects as level 2 evidence [233]. The etanercept stroke
studies, each of which documents dramatic clinical
improvement following perispinal etanercept administra-
tion, therefore provide level 2 evidence of the effectiveness
of perispinal etanercept for post-stroke neurological dys-
function [233–236]. The weight of the evidence calls for
the initiation and funding of the exceedingly costly, large-
scale, randomized controlled trials necessary to obtain US
FDA approval of perispinal etanercept for these indica-
tions. The cost of clinical trials for brain disorders can
exceed $US1 billion [237]. Until such trials are completed,
the elaborated evidence and unmet medical need provide
an ethical mandate that together support this off-label
treatment approach [33, 40, 238–246]. With the additional
weight of recent basic science studies reporting favorable
effects of etanercept in a diverse group of brain disorders,
and scientists from several independent academic centers
reporting favorable effects of TNF inhibition in other
stroke models, now is the time to seriously consider sys-
tematic testing of perispinal etanercept for brain injury,
especially in stroke. Clinical trials should be directed at
early and late post-stroke interventions that can validate the
drug for potential future use.
4 Future Directions
On the 40th anniversary of the journal Stroke, leading
stroke researchers met to devise and prioritize new ways of
accelerating progress in reducing the risks, effects, and
consequences of stroke [3]. Their consensus recommen-
dations regarding stroke research included the following
[3]:
‘‘[T]here is clearly a need to ‘‘do things differently’’
if there is to be a major advance in the development
of new interventions…We need to scan the scientific
landscape to embrace new ideas and approaches …
Be alert to new models of disease that may vertically
integrate basic, clinical, and epidemiological disci-
plines. For example, could advances in the under-
standing of infectious disease or inflammation
dramatically change our thinking about stroke path-
ogenesis?’’ [3]
Scientific communities do not easily embrace new ideas,
despite the calls of its leaders to do so [3, 36, 247–252]. As
Wolinsky has stated, ‘‘the advancement of scientific
knowledge is an uphill struggle against ‘accepted
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wisdom’’’ [36]. Recognition that chronic microglial acti-
vation, synaptic plasticity, and pathologic TNF concentra-
tion are therapeutic targets that may be therapeutically
addressed for years following stroke and other forms of
acute brain injury provides an exciting new direction for
research and treatment.
Acknowledgments and Conflict Disclosure None of the authors
received funding for writing this paper. Authors Butterworth, Folk-
ersma, and Dhandapani have no conflicts of interest. The authors
thank Nigel Grieg and David Tweedie, both from the Laboratory of
Neurosciences, National Institute on Aging Intramural Research
Program, Baltimore, Maryland, for their contributions to the text in
the sections describing the experimental results of thalidomide ana-
logs. Edward Tobinick has multiple issued and pending US and for-
eign patents, assigned to TACT IP, LLC, that claim methods of use of
etanercept for treatment of neurological disorders, including but not
limited to US patents 6419944, 6537549, 6982089, 7214658,
7629311, 8119127, 8236306, and 8349323, all assigned to TACT IP,
LLC; and Australian patent 758523. Dr. Tobinick is the founder of the
Institute of Neurological Recovery, a group of medical practices that
utilize perispinal etanercept as a therapeutic modality, and also train
physicians; and he is the CEO of TACT IP, LLC. Tracey Ignatowski
and Robert Spengler have been unpaid expert witnesses for the INR.
Tracey Ignatowski and Robert Spengler’s professional activities
include their work as co-directors of neuroscience at NanoAxis, LLC,
a company formed to foster the commercial development of products
and applications in the field of nanomedicine that include novel
methods of inhibiting TNF. The article represents the authors’ own
work in which NanoAxis, LLC was not involved.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
References
1. Mendis S. Stroke disability and rehabilitation of stroke: World
Health Organization perspective. Int J Stroke. 2013;8(1):3–4.
2. Skolarus LE, Burke JF, Brown DL, Freedman VA. Under-
standing stroke survivorship: expanding the concept of post-
stroke disability. Stroke. 2014;45(1):224–30.
3. Hachinski V, Donnan GA, Gorelick PB, Hacke W, Cramer SC,
Kaste M, et al. Stroke: working toward a prioritized world
agenda. Stroke. 2010;41(6):1084–99.
4. Tobinick E. Rapid improvement of chronic stroke deficits after
perispinal etanercept: three consecutive cases. CNS Drugs.
2011;25(2):145–55.
5. Tobinick E, Kim NM, Reyzin G, Rodriguez-Romanacce H,
Depuy V. Selective TNF inhibition for chronic stroke and
traumatic brain injury: an observational study involving 629
consecutive patients treated with perispinal etanercept. CNS
Drugs. 2012;26(12):1051–70.
6. Banks WA, Plotkin SR, Kastin AJ. Permeability of the blood-
brain barrier to soluble cytokine receptors. Neuroimmunomod-
ulation. 1995;2(3):161–5.
7. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H,
et al. Peripherally administered antibodies against amyloid beta-
peptide enter the central nervous system and reduce pathology in
a mouse model of Alzheimer disease. Nat Med. 2000;6(8):
916–9.
8. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M,
Damon L, et al. Rituximab therapy for CNS lymphomas: tar-
geting the leptomeningeal compartment. Blood.
2003;101(2):466–8.
9. Bacher M, Depboylu C, Du Y, Noelker C, Oertel WH, Behr T,
et al. Peripheral and central biodistribution of (111)In-labeled
anti-beta-amyloid autoantibodies in a transgenic mouse model
of Alzheimer’s disease. Neurosci Lett. 2009;449(3):240–5.
10. Tobinick E. Perispinal etanercept: a new therapeutic paradigm
in neurology. Expert Rev Neurother. 2010;10(6):985–1002.
11. Tobinick E, Rodriguez-Romanacce H, Levine A, Ignatowski
TA, Spengler RN. Immediate neurological recovery following
perispinal etanercept years after brain injury. Clin Drug Investig.
2014;34(5):361–6.
12. Batson OV. The function of the vertebral veins and their role in
the spread of metastases. Ann Surg. 1940;112(1):138–49.
13. LaBan MM, Chamberlain CC, Jaiyesimi I, Shetty AN, Wang
AM. Paravertebral muscle metastases as imaged by magnetic
resonance venography: a brief report. Am J Phys Med Rehabil.
1998;77(6):553–6.
14. Anderson R. Diodrast studies of the vertebral and cranial venous
systems to show their probable role in cerebral metastases.
J Neurosurg. 1951;8(4):411–22.
15. Batson OV. The vertebral vein system. Caldwell lecture, 1956.
Am J Roentgenol Radium Ther Nucl Med. 1957;78(2):195–212.
16. Tobinick E, Vega CP. The cerebrospinal venous system: anat-
omy, physiology, and clinical implications. MedGenMed.
2006;8(1):53.
17. Tubbs RS, Hansasuta A, Loukas M, Louis RG Jr, Shoja MM,
Salter EG, et al. The basilar venous plexus. Clin Anat.
2007;20(7):755–9.
18. Nathoo N, Caris EC, Wiener JA, Mendel E. History of the
vertebral venous plexus and the significant contributions of
Breschet and Batson. Neurosurgery. 2011;69(5):1007-14; dis-
cussion 14.
19. Pearce JM. The craniospinal venous system. Eur Neurol.
2006;56(2):136–8.
20. Etz CD, Luehr M, Kari FA, Bodian CA, Smego D, Plestis KA,
et al. Paraplegia after extensive thoracic and thoracoabdominal
aortic aneurysm repair: does critical spinal cord ischemia occur
postoperatively? J Thorac Cardiovasc Surg. 2008;135(2):
324–30.
21. De Wyngaert R, Casteels I, Demaerel P. Orbital and anterior
visual pathway infection and inflammation. Neuroradiology.
2009;51(6):385–96.
22. Gasco J, Kew Y, Livingston A, Rose J, Zhang YJ. Dissemina-
tion of prostate adenocarcinoma to the skull base mimicking
giant trigeminal schwannoma: anatomic relevance of the extra-
dural neural axis component. Skull Base. 2009;19(6):425–30.
23. Morimoto A, Takase I, Shimizu Y, Nishi K. Assessment of
cervical venous blood flow and the craniocervical venus valve
using ultrasound sonography. Leg Med. 2009;11(1):10–7.
24. Dumont TM, Stockwell DW, Horgan MA. Venous air embo-
lism: an unusual complication of atlantoaxial arthrodesis: case
report. Spine. 2010;35(22):E1238–40.
25. Dabus G, Batjer HH, Hurley MC, Nimmagadda A, Russell EJ.
Endovascular treatment of a bilateral dural carotid-cavernous
fistula using an unusual unilateral approach through the basilar
plexus. World Neurosurg. 2012;77(1):201 e5–8.
26. Hojlund J, Sandmand M, Sonne M, Mantoni T, Jorgensen HL,
Belhage B, et al. Effect of head rotation on cerebral blood
velocity in the prone position. Anesthesiol Res Pract.
2012;2012:647258.
27. Blaylock RL. Immunology primer for neurosurgeons and neu-
rologists part 2: Innate brain immunity. Surg Neurol Int.
2013;4:118.
Etanercept Post-Stroke: Rationale and Evidence 691
28. Puri AS, Telischak NA, Vissapragada R, Thomas AJ. Analysis
of venous drainage in three patients with extradural spinal
arteriovenous fistulae at the craniovertebral junction with
potentially benign implication. J Neurointerv Surg. 2014;6(2):
105-5
29. Strong C, Yanamadala V, Khanna A, Walcott BP, Nahed BV,
Borges LF, et al. Surgical treatment options and management
strategies of metastatic renal cell carcinoma to the lumbar spinal
nerve roots. J Clin Neurosci. 2013;20(11):1546–9.
30. Griessenauer CJ, Raborn J, Foreman P, Shoja MM, Loukas M,
Tubbs RS. Venous drainage of the spine and spinal cord: A
comprehensive review of its history, embryology, anatomy,
physiology, and pathology. Clin Anat. 2014 Feb 22 [Epub ahead
of print].
31. Tobinick EL, Chen K, Chen X. Rapid intracerebroventricular
delivery of Cu-DOTA-etanercept after peripheral administration
demonstrated by PET imaging. BMC Res Notes. 2009;2:28.
32. Clark IA, Alleva LM, Vissel B. The roles of TNF in brain
dysfunction and disease. Pharmacol Ther. 2010;128(3):519–48.
33. Clark I. New hope for survivors of stroke and traumatic brain
injury. CNS Drugs. 2012;26(12):1071–2.
34. Clark I, Atwood C, Bowen R, Paz-Filho G, Vissel B. Tumor
necrosis factor-induced cerebral insulin resistance in Alzhei-
mer’s disease links numerous treatment rationales. Pharmacol
Rev. 2012;64(4):1004–26.
35. Tobinick E. Deciphering the physiology underlying the rapid
clinical effects of perispinal etanercept in Alzheimer’s disease.
Curr Alzheimer Res. 2012;9(1):99–109.
36. Wolinsky H. Paths to acceptance. The advancement of scientific
knowledge is an uphill struggle against ‘accepted wisdom’.
EMBO Rep. 2008;9(5):416–8.
37. Hill AB. The environment and disease: association or causation?
Proc Royal Soc Med. 1965;58:295–300.
38. Miklossy J. Alzheimer’s disease - a neurospirochetosis. Analysis
of the evidence following Koch’s and Hill’s criteria. J Neuroin-
flammation. 2011;8:90.
39. See A. Use of human epidemiology studies in proving causation.
Def Counsel J. 2000;67:478–87.
40. Kaplan BJ, Giesbrecht G, Shannon S, McLeod K. Evaluating
treatments in health care: the instability of a one-legged stool.
BMC Med Res Methodol. 2011;11:65.
41. Sumbria RK, Boado RJ, Pardridge WM. Brain protection from
stroke with intravenous TNFalpha decoy receptor-Trojan horse
fusion protein. J Cereb Blood Flow Metab. 2012;32(10):1933–8.
42. King MD, Alleyne CH Jr, Dhandapani KM. TNF-alpha receptor
antagonist, R-7050, improves neurological outcomes following
intracerebral hemorrhage in mice. Neurosci Lett. 2013;
542:92–6.
43. Lei B, Dawson HN, Roulhac-Wilson B, Wang H, Laskowitz DT,
James ML. Tumor necrosis factor alpha antagonism improves
neurological recovery in murine intracerebral hemorrhage.
J Neuroinflamm. 2013;10(1):103.
44. Works MG, Koenig JB, Sapolsky RM. Soluble TNF receptor
1-secreting ex vivo-derived dendritic cells reduce injury after
stroke. J Cereb Blood Flow Metab. 2013;33(9):1376-85.
45. Chio CC, Lin JW, Chang MW, Wang CC, Kuo JR, Yang CZ,
et al. Therapeutic evaluation of etanercept in a model of trau-
matic brain injury. J Neurochem. 2010;115(4):921–9.
46. Esposito E, Cuzzocrea S. Anti-TNF therapy in the injured spinal
cord. Trends Pharmacol Sci. 2011;32(2):107–15.
47. Wade DT, Wood VA, Heller A, Maggs J, Langton Hewer R.
Walking after stroke. Measurement and recovery over the first
3 months. Scand J Rehabil Med. 1987;19(1):25–30.
48. Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS. Recovery
of walking function in stroke patients: the Copenhagen Stroke
Study. Arch Phys Med Rehabil. 1995;76(1):27–32.
49. Friedman PJ. Gait recovery after hemiplegic stroke. Int Disabil
Stud. 1990;12(3):119–22.
50. Pettygrove S. Dose-response relationship. Encycl Epidemiol.
2008;1:282–3.
51. Clark IA, Chaudhri G, Cowden WB. Roles of tumour necrosis
factor in the illness and pathology of malaria. Trans R Soc Trop
Med Hyg. 1989;83(4):436–40.
52. Goodman JC, Robertson CS, Grossman RG, Narayan RK. Ele-
vation of tumor necrosis factor in head injury. J Neuroimmunol.
1990;30(2–3):213–7.
53. Perry RT, Collins JS, Wiener H, Acton R, Go RC. The role of
TNF and its receptors in Alzheimer’s disease. Neurobiol Aging.
2001;22(6):873–83.
54. Sjogren M, Folkesson S, Blennow K, Tarkowski E. Increased
intrathecal inflammatory activity in frontotemporal dementia:
pathophysiological implications. J Neurol Neurosurg Psychiatry.
2004;75(8):1107–11.
55. Tweedie D, Sambamurti K, Greig NH. TNF-alpha inhibition as
a treatment strategy for neurodegenerative disorders: new drug
candidates and targets. Curr Alzheimer Res. 2007;4(4):378–85.
56. John CC, Panoskaltsis-Mortari A, Opoka RO, Park GS, Orchard
PJ, Jurek AM, et al. Cerebrospinal fluid cytokine levels and
cognitive impairment in cerebral malaria. Am J Trop Med Hyg.
2008;78(2):198–205.
57. Terrando N, Monaco C, Ma D, Foxwell BM, Feldmann M, Maze
M. Tumor necrosis factor-alpha triggers a cytokine cascade
yielding postoperative cognitive decline. Proc Natl Acad Sci U S
A. 2010;107(47):20518-22.
58. Butterworth RF. Neuroinflammation in acute liver failure:
mechanisms and novel therapeutic targets. Neurochem Int.
2011;59(6):830–6.
59. Frankola KA, Greig NH, Luo W, Tweedie D. Targeting TNF-
alpha to elucidate and ameliorate neuroinflammation in neuro-
degenerative diseases. CNS Neurol Disord Drug Targets.
2011;10(3):391–403.
60. Cheong CU, Chang CP, Chao CM, Cheng BC, Yang CZ, Chio
CC. Etanercept attenuates traumatic brain injury in rats by
reducing brain TNF-alpha contents and by stimulating newly
formed neurogenesis. Mediators Inflamm. 2013;2013:620837.
61. Chio CC, Chang CH, Wang CC, Cheong CU, Chao CM, Cheng
BC, et al. Etanercept attenuates traumatic brain injury in rats by
reducing early microglial expression of tumor necrosis factor-
alpha. BMC Neurosci. 2013;14(1):33.
62. Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm
VE, Cleveland CM, et al. TDP-43 frontotemporal lobar degen-
eration and autoimmune disease. J Neurol Neurosurg Psychiatry.
2013;84(9):956–62.
63. Tracey D, Klareskog L, Sasso EH, Salfeld JG. Tak PP. Tumor
necrosis factor antagonist mechanisms of action: a comprehen-
sive review. Pharmacol Ther. 2008;117(2):244–79.
64. Marchand F, Tsantoulas C, Singh D, Grist J, Clark AK, Brad-
bury EJ, et al. Effects of etanercept and minocycline in a rat
model of spinal cord injury. Eur J Pain. 2009;13(7):673–81.
65. Shen CH, Tsai RY, Shih MS, Lin SL, Tai YH, Chien CC, et al.
Etanercept restores the antinociceptive effect of morphine and
suppresses spinal neuroinflammation in morphine-tolerant rats.
Anesth Analg. 2011;112(2):454–9.
66. Roh M, Zhang Y, Murakami Y, Thanos A, Lee SC, Vavvas DG,
et al. Etanercept, a widely used inhibitor of tumor necrosis
factor-alpha (TNF-alpha), prevents retinal ganglion cell loss in a
rat model of glaucoma. PLoS One. 2012;7(7):e40065.
67. Butterworth RF. The liver-brain axis in liver failure: neuroin-
flammation and encephalopathy. Nat Rev Gastroenter Hepatol.
2013;10(9):522–8.
68. Tobinick E. Perispinal etanercept for neuroinflammatory disor-
ders. Drug Discov Today. 2009;14(3–4):168–77.
692 T. A. Ignatowski et al.
69. Tobinick E. Tumour necrosis factor modulation for treatment of
Alzheimer’s disease: rationale and current evidence. CNS
Drugs. 2009;23(9):713–25.
70. Breschet G. Essai sur les veines du rachis [Theses presentees et
soutenues publiq. devant les juges concours le 28. Avril 1819].
Paris: Faculte de Medecine de Paris; 1819.
71. Breschet G. Recherches anatomiques physiologiques et patholog-
iques sur le systa´eme veineux. Paris: Rouen fra´eres; 1829. p. 48.
72. Gray H, Holmes T. Anatomy, descriptive and surgical. 4th ed.
London: Longmans, Green, and Co.; 1866.
73. Quain J. The elements of anatomy, 7 ed. 7th ed. London: James
Walton; 1867.
74. Herlihy WF. Revision of the venous system; the role of the
vertebral veins. Med J Aust. 1947;1(22):661–72.
75. Netter FH, Ciba Pharmaceutical Products inc., CIBA-GEIGY
Corporation. The Ciba collection of medical illustrations : a
compilation of pathological and anatomical paintings. Summit
(NJ): Ciba Pharmaceutical Products; 1958.
76. Groen RJ, Groenewegen HJ, van Alphen HA, Hoogland PV.
Morphology of the human internal vertebral venous plexus: a
cadaver study after intravenous Araldite CY 221 injection. Anat
Rec. 1997;249(2):285–94.
77. LaBan MM, Wilkins JC, Szappanyos B, Shetty AN, Wang AM.
Paravertebral plexus of veins (Batson’s)—potential route of
paraspinal muscle metastases as imaged by magnetic venous
angiography. A commentary. Am J Phys Med Rehabil.
1997;76(6):517–9.
78. Groen RJ, du Toit DF, Phillips FM, Hoogland PV, Kuizenga K,
Coppes MH, et al. Anatomical and pathological considerations
in percutaneous vertebroplasty and kyphoplasty: a reappraisal of
the vertebral venous system. Spine (Phila Pa 1976).
2004;29(13):1465–71.
79. Griessenauer CJ, Raborn J, Foreman P, Shoja MM, Loukas M,
Tubbs RS. Venous drainage of the spine and spinal cord: a com-
prehensive review of its history, embryology, anatomy, physiology,
and pathology. Clin Anat. 2014 Feb 22 [Epub ahead of print].
80. Feuerstein GZ, Liu T, Barone FC. Cytokines, inflammation, and
brain injury: role of tumor necrosis factor-alpha. Cerebrovasc
Brain Metab Rev. 1994;6(4):341–60.
81. Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette
RN, et al. Tumor necrosis factor-alpha. A mediator of focal
ischemic brain injury. Stroke. 1997;28(6):1233–44.
82. Nawashiro H, Martin D, Hallenbeck JM. Neuroprotective effects
of TNF binding protein in focal cerebral ischemia. Brain Res.
1997;778(2):265–71.
83. Zaremba J. Contribution of tumor necrosis factor alpha to the
pathogenesis of stroke. Folia Morphol (Warsz). 2000;59(3):
137–43.
84. Zaremba J, Losy J. Early TNF-alpha levels correlate with
ischaemic stroke severity. Acta Neurol Scand. 2001;104(5):
288–95.
85. Zaremba J, Skrobanski P, Losy J. Tumour necrosis factor-alpha
is increased in the cerebrospinal fluid and serum of ischaemic
stroke patients and correlates with the volume of evolving brain
infarct. Biomed Pharmacother. 2001;55(5):258–63.
86. Kaushal V, Schlichter LC. Mechanisms of microglia-mediated
neurotoxicity in a new model of the stroke penumbra. J Neuro-
sci. 2008;28(9):2221–30.
87. Siniscalchi A, Gallelli L, Malferrari G, Pirritano D, Serra R,
Santangelo E, et al. Cerebral stroke injury: the role of cytokines
and brain inflammation. J Basic Clin Physiol Pharmacol.
2014;25(2):131-7.
88. Liu T, Clark RK, McDonnell PC, Young PR, White RF, Barone
FC, et al. Tumor necrosis factor-alpha expression in ischemic
neurons. Stroke. 1994;25(7):1481–8.
89. Arvin B, Neville LF, Barone FC, Feuerstein GZ. The role of
inflammation and cytokines in brain injury. Neurosci Biobehav
Rev. 1996;20(3):445–52.
90. Kooijman E, Nijboer CH, van Velthoven CT, Mol W, Dijkhu-
izen RM, Kesecioglu J, et al. Long-term functional conse-
quences and ongoing cerebral inflammation after subarachnoid
hemorrhage in the rat. PLoS One. 2014;9(3):e90584.
91. Aronowski J, Hall CE. New horizons for primary intracerebral
hemorrhage treatment: experience from preclinical studies.
Neurol Res. 2005;27(3):268–79.
92. Mayne M, Ni W, Yan HJ, Xue M, Johnston JB, Del Bigio MR,
et al. Antisense oligodeoxynucleotide inhibition of tumor
necrosis factor-alpha expression is neuroprotective after intra-
cerebral hemorrhage. Stroke. 2001;32(1):240–8.
93. Xi G, Hua Y, Keep RF, Younger JG, Hoff JT. Systemic com-
plement depletion diminishes perihematomal brain edema in
rats. Stroke. 2001;32(1):162–7.
94. Lu A, Tang Y, Ran R, Ardizzone TL, Wagner KR, Sharp FR.
Brain genomics of intracerebral hemorrhage. J Cereb Blood
Flow Metab. 2006;26(2):230–52.
95. Wagner KR, Beiler S, Beiler C, Kirkman J, Casey K, Robinson
T, et al. Delayed profound local brain hypothermia markedly
reduces interleukin-1beta gene expression and vasogenic edema
development in a porcine model of intracerebral hemorrhage.
Acta Neurochir Suppl. 2006;96:177–82.
96. Wasserman JK, Zhu X, Schlichter LC. Evolution of the
inflammatory response in the brain following intracerebral
hemorrhage and effects of delayed minocycline treatment. Brain
Res. 2007;1180:140-54.
97. Kim JS, Yoon SS, Kim YH, Ryu JS. Serial measurement of
interleukin-6, transforming growth factor-beta, and S-100 pro-
tein in patients with acute stroke. Stroke. 1996;27(9):1553–7.
98. Castillo J, Davalos A, Alvarez-Sabin J, Pumar JM, Leira R,
Silva Y, et al. Molecular signatures of brain injury after intra-
cerebral hemorrhage. Neurology. 2002;58(4):624–9.
99. Dziedzic T, Bartus S, Klimkowicz A, Motyl M, Slowik A,
Szczudlik A. Intracerebral hemorrhage triggers interleukin-6
and interleukin-10 release in blood. Stroke. 2002;33(9):2334–5.
100. Woiciechowsky C, Schoning B, Cobanov J, Lanksch WR, Volk
HD, Docke WD. Early IL-6 plasma concentrations correlate
with severity of brain injury and pneumonia in brain-injured
patients. J Trauma. 2002;52(2):339–45.
101. Fang HY, Ko WJ, Lin CY. Inducible heat shock protein 70,
interleukin-18, and tumor necrosis factor alpha correlate with
outcomes in spontaneous intracerebral hemorrhage. J Clin
Neurosci. 2007;14(5):435–41.
102. Hua Y, Wu J, Keep RF, Nakamura T, Hoff JT, Xi G. Tumor
necrosis factor-alpha increases in the brain after intracerebral
hemorrhage and thrombin stimulation. Neurosurgery.
2006;58(3):542–50; discussion -50.
103. Ashkenazi A, Dixit VM. Death receptors: signaling and modu-
lation. Science. 1998;281(5381):1305–8.
104. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF
receptor superfamilies: integrating mammalian biology. Cell.
2001;104(4):487–501.
105. Gururaja TL, Yung S, Ding R, Huang J, Zhou X, McLaughlin J,
et al. A class of small molecules that inhibit TNFalpha-induced
survival and death pathways via prevention of interactions
between TNFalphaRI, TRADD, and RIP1. Chem Biol.
2007;14(10):1105–18.
106. Galustian C, Labarthe M-C, Bartlett JB, Dalgleish AG. Tha-
lidomide-derived immunomodulatory drugs as therapeutic
agents. Expert Opin Biol Ther. 2004;4(12):1963–70.
107. De Sanctis JB, Mijares M, Suarez A, Compagnone R, Gar-
mendia J, Moreno D, et al. Pharmacological properties of
Etanercept Post-Stroke: Rationale and Evidence 693
thalidomide and its analogues. Recent Pat Inflamm Allergy Drug
Discov. 2010;4(2):144–8.
108. Zhu X, Giordano T, Yu QS, Holloway HW, Perry TA, Lahiri
DK, et al. Thiothalidomides: novel isosteric analogues of tha-
lidomide with enhanced TNF-alpha inhibitory activity. J Med
Chem. 2003;46(24):5222–9.
109. Baratz R, Tweedie D, Rubovitch V, Luo W, Yoon JS, Hoffer BJ,
et al. Tumor necrosis factor-alpha synthesis inhibitor, 3,6’-di-
thiothalidomide, reverses behavioral impairments induced by
minimal traumatic brain injury in mice. J Neurochem.
2011;118(6):1032–42.
110. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA,
Kaplan G. Thalidomide exerts its inhibitory action on tumor
necrosis factor alpha by enhancing mRNA degradation. J Exp
Med. 1993;177(6):1675–80.
111. Li S, Pal R, Monaghan SA, Schafer P, Ouyang H, Mapara M,
et al. IMiD immuno-modulatory compounds block C/EBP{beta}
translation through eIF4E down- regulation resulting in inhibi-
tion of MM. Blood. 2011;117(19):5157–65.
112. Yoon JS, Lee JH, Tweedie D, Mughal MR, Chigurupati S, Greig
NH, et al. 3,6’-dithiothalidomide improves experimental stroke
outcome by suppressing neuroinflammation. J Neurosci Res.
2013;91(5):671–80.
113. Mayhan WG. Cellular mechanisms by which tumor necrosis
factor-alpha produces disruption of the blood–brain barrier.
Brain Res. 2002;927(2):144–52.
114. Pan W, Kastin AJ. Tumor necrosis factor and stroke: role of the
blood-brain barrier. Prog Neurobiol. 2007;83(6):363–74.
115. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC.
Matrix metalloproteinase expression increases after cerebral
focal ischemia in rats: inhibition of matrix metalloproteinase-9
reduces infarct size. Stroke. 1998;29(5):1020–30.
116. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ,
et al. Role of matrix metalloproteinases in delayed cortical
responses after stroke. Nat Med. 2006;12(4):441–5.
117. Takata F, Dohgu S, Matsumoto J, Takahashi H, Machida T,
Wakigawa T, et al. Brain pericytes among cells constituting the
blood-brain barrier are highly sensitive to tumor necrosis factor-
a, releasing matrix metalloproteinase-9 and migrating in vitro.
J Neuroinflammation. 2011;8(106):1–12.
118. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri
ES, Baehrecke EH, et al. Classification of cell death: recom-
mendations of the Nomenclature Committee on Cell Death
2009. Cell Death Differ. 2009;16(1):3–11.
119. Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of
programmed necrosis. Cell. 2008;135(7):1161–3.
120. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier
RJ, et al. Identification of a molecular signaling network that
regulates a cellular necrotic cell death pathway. Cell.
2008;135(7):1311–23.
121. Kitanaka C, Kuchino Y. Caspase-independent programmed cell
death with necrotic morphology. Cell Death Differ. 1999;6(6):
508–15.
122. Laird MD, Wakade C, Alleyne CH Jr, Dhandapani KM. Hemin-
induced necroptosis involves glutathione depletion in mouse
astrocytes. Free Radic Biol Med. 2008;45(8):1103–14.
123. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P.
The death domain kinase RIP mediates the TNF-induced NF-
kappaB signal. Immunity. 1998;8(3):297–303.
124. Degterev A, Hitomi J, Germscheid M, Ch’en IL, Korkina O,
Teng X, et al. Identification of RIP1 kinase as a specific cellular
target of necrostatins. Nat Chem Biol. 2008;4(5):313–21.
125. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N,
et al. Chemical inhibitor of nonapoptotic cell death with thera-
peutic potential for ischemic brain injury. Nat Chem Biol.
2005;1(2):112–9.
126. King MD, Whitaker-Lea WA, Campbell J, Alleyne CH,
Dhandapani KM. Necrostatin-1 reduces neurovascular injury
after intracerebral hemorrhage. Int J Cell Biol. 2014 Mar 6
[Epub ahead of print]
127. Xu X, Chua KW, Chua CC, Liu CF, Hamdy RC, Chua BH.
Synergistic protective effects of humanin and necrostatin-1 on
hypoxia and ischemia/reperfusion injury. Brain Res.
2010;1355:189–94.
128. You Z, Savitz SI, Yang J, Degterev A, Yuan J, Cuny GD, et al.
Necrostatin-1 reduces histopathology and improves functional
outcome after controlled cortical impact in mice. J Cereb Blood
Flow Metab. 2008;28(9):1564–73.
129. Knoblach SM, Fan L, Faden AI. Early neuronal expression of
tumor necrosis factor-alpha after experimental brain injury
contributes to neurological impairment. J Neuroimmunol.
1999;95(1–2):115–25.
130. Low PC, Manzanero S, Mohannak N, Narayana VK, Nguyen
TH, Kvaskoff D, et al. PI3Kdelta inhibition reduces TNF
secretion and neuroinflammation in a mouse cerebral stroke
model. Nat Commun. 2014;5:3450.
131. Dubois A, Benavides J, Peny B, Duverger D, Fage D, Gotti B,
et al. Imaging of primary and remote ischaemic and excitotoxic
brain lesions. An autoradiographic study of peripheral type
benzodiazepine binding sites in the rat and cat. Brain Res.
1988;445(1):77–90.
132. Myers R, Manjil LG, Frackowiak RS, Cremer JE. [3H]PK
11195 and the localisation of secondary thalamic lesions fol-
lowing focal ischaemia in rat motor cortex. Neurosci Lett.
1991;133(1):20–4.
133. Pappata S, Levasseur M, Gunn RN, Myers R, Crouzel C, Syrota
A, et al. Thalamic microglial activation in ischemic stroke
detected in vivo by PET and [11C]PK1195. Neurology.
2000;55(7):1052–4.
134. Gentleman SM, Leclercq PD, Moyes L, Graham DI, Smith C,
Griffin WS, et al. Long-term intracerebral inflammatory
response after traumatic brain injury. Forensic Sci Int.
2004;146(2–3):97–104.
135. Gerhard A, Schwarz J, Myers R, Wise R, Banati RB. Evolution
of microglial activation in patients after ischemic stroke: a
[11C](R)-PK11195 PET study. Neuroimage. 2005;24(2):591–5.
136. Price CJ, Wang D, Menon DK, Guadagno JV, Cleij M, Fryer T,
et al. Intrinsic activated microglia map to the peri-infarct zone in
the subacute phase of ischemic stroke. Stroke J Cereb Circ.
2006;37(7):1749–53.
137. Folkersma H, Boellaard R, Yaqub M, Kloet RW, Windhorst AD,
Lammertsma AA, et al. Widespread and prolonged increase in
(R)-(11)C-PK11195 binding after traumatic brain injury. J Nucl
Med. 2011;52(8):1235–9.
138. Ramlackhansingh AF, Brooks DJ, Greenwood RJ, Bose SK,
Turkheimer FE, Kinnunen KM, et al. Inflammation after trauma:
microglial activation and traumatic brain injury. Ann Neurol.
2011;70(3):374–83.
139. Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith
DH, Stewart W. Inflammation and white matter degeneration
persist for years after a single traumatic brain injury. Brain J
Neurol. 2013;136(Pt 1):28–42.
140. Hughes JL, Beech JS, Jones PS, Wang D, Menon DK, Baron JC.
Mapping selective neuronal loss and microglial activation in the
salvaged neocortical penumbra in the rat. Neuroimage.
2010;49(1):19–31.
141. Tancredi V, D’Arcangelo G, Grassi F, Tarroni P, Palmieri G,
Santoni A, et al. Tumor necrosis factor alters synaptic transmission
in rat hippocampal slices. Neurosci Lett. 1992;146(2):176–8.
142. Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK,
Von Zastrow M, et al. Control of synaptic strength by glial
TNFalpha. Science. 2002;295(5563):2282–5.
694 T. A. Ignatowski et al.
143. Pickering M, Cumiskey D, O’Connor JJ. Actions of TNF-alpha
on glutamatergic synaptic transmission in the central nervous
system. Exp Physiol. 2005;90(5):663–70.
144. Stellwagen D, Malenka RC. Synaptic scaling mediated by glial
TNF-alpha. Nature. 2006;440(7087):1054–9.
145. Bains JS, Oliet SH. Glia: they make your memories stick!.
Trends Neurosci. 2007;30(8):417–24.
146. Tobinick E. Perispinal etanercept for treatment of Alzheimer’s
disease. Curr Alzheimer Res. 2007;4(5):550–2.
147. Wang Y. P4-266: Modification of synaptic plasticity by TNF and
sphingomyelinase: Implications for cognitive impairment in Alz-
heimer’s disease. Alzheimer Dement. 2008;4(4 Supplement):T749.
148. Nygard M, Lundkvist GB, Hill RH, Kristensson K. Rapid nitric
oxide-dependent effects of tumor necrosis factor-alpha on sup-
rachiasmatic nuclei neuronal activity. Neuroreport.
2009;20(2):213–7.
149. Wheeler D, Knapp E, Bandaru VV, Wang Y, Knorr D, Poirier C,
et al. Tumor necrosis factor-alpha-induced neutral sphingomy-
elinase-2 modulates synaptic plasticity by controlling the
membrane insertion of NMDA receptors. J Neurochem.
2009;109(5):1237–49.
150. Beattie MS, Ferguson AR, Bresnahan JC. AMPA-receptor
trafficking and injury-induced cell death. Eur J Neurosci.
2010;32(2):290–7.
151. Cavanagh C, Colby-Milley J, Farso M, Krantic S, Quirion R.
Early molecular and synaptic dysfunctions in the prodromal
stages of Alzheimer’s disease: focus on TNF-alpha and IL-
1Beta. Future Neurol. 2011;6(6):757–69.
152. Rossi D, Martorana F, Brambilla L. Implications of gliotrans-
mission for the pharmacotherapy of CNS disorders. CNS Drugs.
2011;25(8):641–58.
153. Santello M, Volterra A. TNFalpha in synaptic function:
switching gears. Trends Neurosci. 2012;35(10):638–47.
154. Brambilla L, Martorana F, Rossi D. Astrocyte signaling and
neurodegeneration: new insights into CNS disorders. Prion.
2013;7(1):28–36.
155. Faingold CL. Chapter 7: network control mechanisms: cellular
inputs, neuroactive substances, and synaptic changes. In: Fain-
gold CL, Blumenfeld H, editors. Neuronal Networks in Brain
Function, CNS Disorders, and Therapeutics. Elsevier; 2014.
156. Sommer C, Schmidt C, George A. Hyperalgesia in experimental
neuropathy is dependent on the TNF receptor 1. Exp Neurol.
1998;151(1):138–42.
157. Lindenlaub T, Teuteberg P, Hartung T, Sommer C. Effects of
neutralizing antibodies to TNF-alpha on pain-related behavior
and nerve regeneration in mice with chronic constriction injury.
Brain Res. 2000;866(1–2):15–22.
158. Sommer C, Lindenlaub T, Teuteberg P, Schafers M, Hartung T,
Toyka KV. Anti-TNF-neutralizing antibodies reduce pain-rela-
ted behavior in two different mouse models of painful mono-
neuropathy. Brain Res. 2001;913(1):86–9.
159. Ignatowski TA, Covey WC, Knight PR, Severin CM, Nickola
TJ, Spengler RN. Brain-derived TNFalpha mediates neuropathic
pain. Brain Res. 1999;841(1–2):70–7.
160. Covey WC, Ignatowski TA, Knight PR, Spengler RN. Brain-
derived TNFalpha: involvement in neuroplastic changes impli-
cated in the conscious perception of persistent pain. Brain Res.
2000;859(1):113–22.
161. Covey WC, Ignatowski TA, Renauld AE, Knight PR, Nader ND,
Spengler RN. Expression of neuron-associated tumor necrosis
factor alpha in the brain is increased during persistent pain. Reg
Anesth Pain Med. 2002;27(4):357–66.
162. Reynolds JL, Ignatowski TA, Spengler RN. Effect of tumor
necrosis factor-alpha on the reciprocal G-protein-induced regu-
lation of norepinephrine release by the alpha2-adrenergic
receptor. J Neurosci Res. 2005;79(6):779–87.
163. Ignatowski TA, Spengler RN II. Cytokines in the brain, B.
cytokines in brain physiology: cytokines in synaptic function.
In: Phelps C, Korneva E, editors. NeuroImmune biology, Vol 6:
Cytokines and the brain. Amsterdam: Elsevier; 2008. p. 111–44.
164. Martuscello RT, Spengler RN, Bonoiu AC, Davidson BA, He-
linski J, Ding H, et al. Increasing TNF levels solely in the rat
hippocampus produces persistent pain-like symptoms. Pain.
2012;153(9):1871–82.
165. Ignatowski TA, Gerard BA, Bonoiu AC, Mahajan S, Knight PR,
Davidson BA, et al., editors. Reduction of tumor necrosis factor
(TNF) in the hippocampus alleviates neuropathic pain percep-
tion. In: Proceedings of the 4th International Congress on
Neuropathic Pain, 2013. p. 29–35..
166. Sommer C, Schafers M, Marziniak M, Toyka KV. Etanercept
reduces hyperalgesia in experimental painful neuropathy.
J Peripher Nerv Syst. 2001;6(2):67–72.
167. Tobinick EL. Targeted etanercept for treatment-refractory pain
due to bone metastasis: two case reports. Clin Ther.
2003;25(8):2279–88.
168. Tobinick EL. Targeted etanercept for discogenic neck pain:
uncontrolled, open-label results in two adults. Clin Ther.
2003;25(4):1211–8.
169. Tobinick EL, Britschgi-Davoodifar S. Perispinal TNF-alpha
inhibition for discogenic pain. Swiss Med Wkly. 2003;
133(11–12):170–7.
170. Tobinick E, Davoodifar S. Efficacy of etanercept delivered by
perispinal administration for chronic back and/or neck disc-
related pain: a study of clinical observations in 143 patients.
Curr Med Res Opin. 2004;20(7):1075–85.
171. Cohen SP, Bogduk N, Dragovich A, Buckenmaier CC 3rd,
Griffith S, Kurihara C, et al. Randomized, double-blind, pla-
cebo-controlled, dose-response, and preclinical safety study of
transforaminal epidural etanercept for the treatment of sciatica.
Anesthesiology. 2009;110(5):1116–26.
172. Ohtori S, Miyagi M, Eguchi Y, Inoue G, Orita S, Ochiai N, et al.
Epidural administration of spinal nerves with the tumor necrosis
factor-alpha inhibitor, etanercept, compared with dexametha-
sone for treatment of sciatica in patients with lumbar spinal
stenosis: a prospective randomized study. Spine (Phila Pa 1976).
2012;37(6):439–44.
173. Freeman BJ, Ludbrook GL, Hall S, Cousins M, Mitchell B, Jaros
M, et al. Randomized, double-blind, placebo-controlled, trial of
transforaminal epidural etanercept for the treatment of symp-
tomatic lumbar disc herniation. Spine (Phila Pa 1976).
2013;38(23):1986–94.
174. Kaufman EL, Carl A. Biochemistry of back pain. Open Spine J.
2013;5:12–8.
175. Sainoh T, Orita S, Yamauchi K, Suzuki M, Sakuma Y, Kubota
G, et al. Intradiscal administration of tumor necrosis factor-
alpha inhibitor, etanercept, clinically improves intractable dis-
cogenic low back pain: a prospective randomized study. In:
International society for the study of the lumbar spine 40th
annual meeting; Scottsdale (AZ); 2013.
176. Winkelstein BA, Allen KD, Setton LA. Chapter 19: interverte-
bral disc herniation: pathophysiology and emerging therapies.
In: Shapiro IM, Risbud MV, editors. The intervertebral disc.
Wien: Springer; 2014.
177. Zanella JM, Burright EN, Hildebrand K, Hobot C, Cox M,
Christoferson L, et al. Effect of etanercept, a tumor necrosis
factor-alpha inhibitor, on neuropathic pain in the rat chronic
constriction injury model. Spine (Phila Pa 1976).
2008;33(3):227–34.
178. Watanabe K, Yabuki S, Sekiguchi M, Kikuchi S, Konno S. E-
tanercept attenuates pain-related behavior following compres-
sion of the dorsal root ganglion in the rat. Eur Spine J. 2011;
20(11):1877–84.
Etanercept Post-Stroke: Rationale and Evidence 695
179. Coelho SC, Bastos-Pereira AL, Fraga D, Chichorro JG, Zam-
pronio AR. Etanercept reduces thermal and mechanical orofacial
hyperalgesia following inflammation and neuropathic injury.
Eur J Pain. 2014 Jan 7 [Epub ahead of print].
180. Clark IA, Ilschner S, MacMicking JD, Cowden WB. TNF and
Plasmodium berghei ANKA-induced cerebral malaria. Immunol
Lett. 1990;25(1–3):195–8.
181. Clark IA, Rockett KA, Cowden WB. Role of TNF in cerebral
malaria. Lancet. 1991;337(8736):302–3.
182. Clark IA, Cowden WB. Roles of TNF in malaria and other
parasitic infections. Immunol Ser. 1992;56:365–407.
183. Clark IA, Rockett RA, Cowden WB. TNF in cerebral malaria.
Quart J Med. 1993;86(3):217–8.
184. Clark IA. How TNF was recognized as a key mechanism of
disease. Cytokine Growth Factor Rev. 2007;18(3–4):335–43.
185. Clark IA. Along a TNF-paved road from dead parasites in red
cells to cerebral malaria, and beyond. Parasitology.
2009;136(12):1457–68.
186. Ross SA, Halliday MI, Campbell GC, Byrnes DP, Rowlands BJ.
The presence of tumour necrosis factor in CSF and plasma after
severe head injury. Br J Neurosurg. 1994;8(4):419–25.
187. Shohami E, Novikov M, Bass R, Yamin A, Gallily R. Closed
head injury triggers early production of TNF alpha and IL-6 by
brain tissue. J Cereb Blood Flow Metab. 1994;14(4):615–9.
188. Laws SM, Perneczky R, Wagenpfeil S, Muller U, Forstl H,
Martins RN, et al. TNF polymorphisms in Alzheimer disease
and functional implications on CSF beta-amyloid levels. Hum
Mutat. 2005;26(1):29–35.
189. Wang Q, Wu J, Rowan MJ, Anwyl R. Beta-amyloid inhibition
of long-term potentiation is mediated via tumor necrosis factor.
Eur J Neurosci. 2005;22(11):2827–32.
190. Ramos EM, Lin MT, Larson EB, Maezawa I, Tseng LH,
Edwards KL, et al. Tumor necrosis factor alpha and interleukin
10 promoter region polymorphisms and risk of late-onset Alz-
heimer disease. Arch Neurol. 2006;63(8):1165–9.
191. Medeiros R, Prediger RD, Passos GF, Pandolfo P, Duarte FS,
Franco JL, et al. Connecting TNF-alpha signaling pathways to
iNOS expression in a mouse model of Alzheimer’s disease:
relevance for the behavioral and synaptic deficits induced by
amyloid beta protein. J Neurosci. 2007;27(20):5394–404.
192. Di Bona D, Candore G, Franceschi C, Licastro F, Colonna-
Romano G, Camma C, et al. Systematic review by meta-analyses
on the possible role of TNF-alpha polymorphisms in association
with Alzheimer’s disease. Brain Res Rev. 2009;61(2):60–8.
193. Giuliani F, Vernay A, Leuba G, Schenk F. Decreased behavioral
impairments in an Alzheimer mice model by interfering with
TNF-alpha metabolism. Brain Res Bull. 2009;80(4–5):302–8.
194. Sarajarvi T, Helisalmi S, Antikainen L, Makinen P, Koivisto
AM, Herukka SK, et al. An association study of 21 potential
Alzheimer’s disease risk genes in a Finnish population. J Alz-
heimers Dis. 2010;21(3):763–7.
195. Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, et al.
Anti-TNF-alpha reduces amyloid plaques and tau phosphoryla-
tion and induces CD11c-positive dendritic-like cell in the APP/
PS1 transgenic mouse brains. Brain Res. 2011;1368:239–47.
196. Shi JQ, Wang BR, Jiang WW, Chen J, Zhu YW, Zhong LL,
et al. Cognitive improvement with intrathecal administration of
infliximab in a woman with Alzheimer’s disease. J Am Geriatr
Soc. 2011;59(6):1142–4.
197. Butchart J, Holmes C. Systemic and central immunity in alz-
heimer’s disease: therapeutic implications. CNS Neurosci Ther.
2012;18(1):64-76.
198. Maudsley S, Chadwick W. Progressive and unconventional
pharmacotherapeutic approaches to Alzheimer’s disease ther-
apy. Curr Alzheimer Res. 2012;9(1):1–4.
199. Williams M, Coyle JT. Chapter 7: Historical perspectives on the
discovery and development of drugs to treat neurological dis-
orders. In: Barrett JE, Coyle JT, Williams M, editors. Transla-
tional neuroscience: applications in psychiatry, neurology, and
neurodevelopmental disorders. Cambridge: Cambridge Univer-
sity Press; 2012. p. 129–48.
200. Clark IA, Vissel B. Treatment implications of the altered cyto-
kine-insulin axis in neurodegenerative disease. Biochem Phar-
macol. 2013;86(7):862–71.
201. McAfoose J, Baune BT. Evidence for a cytokine model of
cognitive function. Neurosci Biobehav Rev. 2009;33(3):355–66.
202. Trollor JN, Smith E, Baune BT, Kochan NA, Campbell L,
Samaras K, et al. Systemic inflammation is associated with MCI
and its subtypes: the Sydney Memory and Aging Study. Dement
Geriatr Cogn Disord. 2010;30(6):569–78.
203. Camara ML, Corrigan F, Jaehne EJ, Jawahar MC, Anscomb H,
Koerner H, et al. TNF-alpha and its receptors modulate complex
behaviours and neurotrophins in transgenic mice. Psychoneu-
roendocrinology. 2013;38(12):3102–14.
204. Tobinick E. Perispinal etanercept produces rapid improvement
in primary progressive aphasia: identification of a novel, rapidly
reversible TNF-mediated pathophysiologic mechanism. Med-
scape J Med. 2008;10(6):135.
205. Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA,
Drent M. Everyday cognitive failure in sarcoidosis: the preva-
lence and the effect of anti-TNF-alpha treatment. Respiration.
2010;80(3):212–9.
206. Chen YM, Chen HH, Lan JL, Chen DY. Improvement of cog-
nition, a potential benefit of anti-TNF therapy in elderly patients
with rheumatoid arthritis. Joint Bone Spine. 2010;77(4):366–7.
207. Bassi E, De Filippi C. Beneficial neurological effects observed
in a patient with psoriasis treated with etanercept. Am J Clin
Dermatol. 2010;11(Suppl 1):44–5.
208. Butterworth RF. Hepatic encephalopathy: a central neuroin-
flammatory disorder? Hepatology. 2011;53(4):1372–6.
209. D’Mello C, Le T, Swain MG. Cerebral microglia recruit
monocytes into the brain in response to tumor necrosis factor-
alpha signaling during peripheral organ inflammation. J Neuro-
sci. 2009;29(7):2089–102.
210. Bemeur C, Qu H, Desjardins P, Butterworth RF. IL-1 or TNF
receptor gene deletion delays onset of encephalopathy and
attenuates brain edema in experimental acute liver failure.
Neurochem Int. 2010;56(2):213–5.
211. Jiang W, Desjardins P, Butterworth RF. Direct evidence for
central proinflammatory mechanisms in rats with experimental
acute liver failure: protective effect of hypothermia. J Cereb
Blood Flow Metab. 2009;29(5):944–52.
212. Jiang W, Desjardins P, Butterworth RF. Cerebral inflammation
contributes to encephalopathy and brain edema in acute liver
failure: protective effect of minocycline. J Neurochem.
2009;109(2):485–93.
213. Chastre A, Belanger M, Beauchesne E, Nguyen BN, Desjardins
P, Butterworth RF. Inflammatory cascades driven by tumor
necrosis factor-alpha play a major role in the progression of
acute liver failure and its neurological complications. PLoS One.
2012;7(11):e49670.
214. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E 3rd,
Kufe DW. Recombinant human tumor necrosis factor adminis-
tered as a five-day continuous infusion in cancer patients: phase
I toxicity and effects on lipid metabolism. J Clin Oncol.
1988;6(2):344–50.
215. Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K,
Wilmore D, et al. Recombinant human tumor necrosis factor
administered as a 24-hour intravenous infusion. A phase I and
pharmacologic study. J Natl Cancer Inst. 1988;80(13):1039–44.
696 T. A. Ignatowski et al.
216. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha
modulation for treatment of Alzheimer’s disease: a 6-month
pilot study. MedGenMed. 2006;8(2):25.
217. Griffin WS. Perispinal etanercept: potential as an Alzheimer
therapeutic. J Neuroinflamm. 2008;5:3.
218. Tobinick EL, Gross H. Rapid cognitive improvement in Alz-
heimer’s disease following perispinal etanercept administration.
J Neuroinflamm. 2008;5:2.
219. Tobinick EL, Gross H. Rapid improvement in verbal fluency and
aphasia following perispinal etanercept in Alzheimer’s disease.
BMC Neurol. 2008;8:27.
220. Kato K, Kikuchi S, Shubayev VI, Myers RR. Distribution and
tumor necrosis factor-alpha isoform binding specificity of
locally administered etanercept into injured and uninjured rat
sciatic nerve. Neuroscience. 2009;160(2):492–500.
221. Dogrul A, Gul H, Yesilyurt O, Ulas UH, Yildiz O. Systemic and
spinal administration of etanercept, a tumor necrosis factor alpha
inhibitor, blocks tactile allodynia in diabetic mice. Acta Dia-
betol. 2011;48(2):135–42.
222. Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral
production of tumor necrosis factor-alpha, a local neuroprotec-
tive agent, in Alzheimer disease and vascular dementia. J Clin
Immunol. 1999;19(4):223–30.
223. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intra-
thecal inflammation precedes development of Alzheimer’s dis-
ease. J Neurol Neurosurg Psychiatry. 2003;74(9):1200–5.
224. Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciau-
skiene S, Hansson O. Soluble TNF receptors are associated with
Abeta metabolism and conversion to dementia in subjects with
mild cognitive impairment. Neurobiol Aging.
2010;31(11):1877–84.
225. Chou RC, Kane MA, Ghimire S, Gautam S. Tumor necrosis
factor inhibition reduces the incidence of Alzheimer’s disease in
rheumatoid arthritis patients. In: American College of Rheu-
matology Annual Meeting, presentation 6402010.
226. Walsh N. ACR: Anti-TNF drugs may protect against Alzhei-
mer’s. Medpage Today. 2010;9:2010.
227. Gabbita SP, Srivastava MK, Eslami P, Johnson MF, Kobritz
NK, Tweedie D, et al. Early intervention with a small molecule
inhibitor for tumor necrosis factor-alpha prevents cognitive
deficits in a triple transgenic mouse model of Alzheimer’s dis-
ease. J Neuroinflamm. 2012;9:99.
228. Belarbi K, Jopson T, Tweedie D, Arellano C, Luo W, Greig NH,
et al. TNF-alpha protein synthesis inhibitor restores neuronal
function and reverses cognitive deficits induced by chronic
neuroinflammation. J Neuroinflamm. 2012;9:23.
229. McNaull BB, Todd S, McGuinness B, Passmore AP. Inflam-
mation and anti-inflammatory strategies for Alzheimer’s dis-
ease—a mini-review. Gerontology. 2010;56(1):3–14.
230. Detrait ER, Danis B, Lamberty Y, Foerch P. Peripheral
administration of an anti-TNF-alpha receptor fusion protein
counteracts the amyloid induced elevation of hippocampal TNF-
alpha levels and memory deficits in mice. Neurochem Int.
2014;72C:10-13.
231. Bohac D, Burke W, Cotter R, Zheng J, Potter J, Gendelman H.
A 24-week randomized, double-blind, placebo-controlled study
of the efficacy and tolerability of TNFR: Fc (etanercept) in the
treatment of dementia of the Alzheimer type. Neurobiol Aging.
2002;23(1: Supplement 1):S1-S606, abstract 315.
232. Neurex. Meeting on the roles of TNF in brain dysfunction and
disease. Basel; 2012.
233. OCEBM Levels of Evidence Working Group. The Oxford 2011
Levels of Evidence. Oxford Centre for Evidence-Based Medi-
cine. http://www.cebm.net/index.aspx?o=5653 [Internet]. 2011.
234. Smith GC, Pell JP. Parachute use to prevent death and major
trauma related to gravitational challenge: systematic review of
randomised controlled trials. BMJ. 2003;327(7429):1459–61.
235. Aronson JK, Hauben M. Anecdotes that provide definitive evi-
dence. BMJ. 2006;333(7581):1267–9.
236. Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are
randomised trials unnecessary? Picking signal from noise. BMJ.
2007;334(7589):349–51.
237. Sheridan C. J&J’s billion dollar punt on anti-amyloid antibody.
Nat Biotechnol. 2009;27(8):679–81.
238. Guidance for off-label use of drugs. Lancet neurology.
2008;7(4):285
239. Frattarelli DA, Galinkin JL, Green TP, et al. Off-label use of
drugs in children. Pediatrics. 2014;133(3):563-7
240. American Psychiatric Association. The principles of medical
ethics: with annotations especially applicable to psychiatry.
2001st ed. Washington, D.C.: American Psychiatric Associa-
tion; 2001. p. 46.
241. Beck JM, Azari ED. FDA, off-label use, and informed consent:
debunking myths and misconceptions. Food Drug Law J.
1998;53(1):71–104.
242. Demonaco HJ, Ali A, Hippel E. The major role of clinicians in
the discovery of off-label drug therapies. Pharmacotherapy.
2006;26(3):323–32.
243. Ghaemi SN, Goodwin FK. The ethics of clinical innovation in
psychopharmacology: challenging traditional bioethics. Philos
Ethics Humanit Med. 2007;2:26.
244. Horrobin DF. Effective clinical innovation: an ethical impera-
tive. Lancet. 2002;359(9320):1857–8.
245. Vox F, Capron AM, Kraus MF, Alexander GC, Kirschner KL.
Balancing burdens and benefits: ethical issues of off-label pre-
scription pharmaceutical use. PM R. 2013;5(10):882–9.
246. Dacks PA, Bennett DA, Fillit HM. Evidence needs to be
translated, whether or not it is complete. JAMA Neurol.
2014;71(2):137–8.
247. Riggs JE. Tissue-type plasminogen activator should not be used
in acute ischemic stroke. Arch Neurol. 1996;53(12):1306–8.
248. Zivin JA, Simmons JG. tPA for stroke: the story of a contro-
versial drug. Oxford: Oxford University Press; 2010.
249. Grant GJ, Grant AH, Lockwood CJ. Simpson, Semmelweis, and
transformational change. Obstet Gynecol. 2005;106(2):384–7.
250. Kuhn TS. The structure of scientific revolutions. Chicago:
University of Chicago Press; 1962. xv, p. 172.
251. Kuhn TS, Conant J, Haugeland J. The road since structure:
philosophical essays, 1970–1993, with an autobiographical
interview. Chicago: University of Chicago Press; 2000. viii,
p. 335.
252. Bauer HH. Dogmatism in science and medicine: how dominant
theories monopolize research and stifle the search for truth.
Jefferson (NC): McFarland & Co., Inc., Publishers; 2012. vii,
p. 293.
253. Oka T, Wakugawa Y, Hosoi M, Oka K, Hori T. Intracerebro-
ventricular injection of tumor necrosis factor-alpha induces
thermal hyperalgesia in rats. Neuroimmunomodulation.
1996;3(2–3):135–40.
Etanercept Post-Stroke: Rationale and Evidence 697
